The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...

Astellas, Seagen and Merck are investigating enfortumab vedotin plus pembrolizumab as part of an extensive collaboration, which also includes three Phase 3 studies: the EV-302/KEYNOTE-A39 trial ...

Source Reference: Hoimes CJ, et al "Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer" J Clin Oncol 2022; DOI: 10.1200/JCO.22.01643.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

SAN FRANCISCO — Neoadjuvant treatment with enfortumab vedotin demonstrated promising activity among cisplatin-ineligible patients with muscle-invasive bladder cancer, according to study results ...

Results of two studies presented at Genitourinary Cancers Symposium showed treatment with enfortumab vedotin-ejfv benefited patients with locally advanced or metastatic urothelial carcinoma ...